On Thursday, March 2, 2023, Cooper Companies, a major producer of contact lenses and medical equipment, is scheduled to release its financial results. The business has had a successful year, and its stock price has been steadily rising. Recent market signs, however, indicate that the stock may be changing from an upward to a bearish trend.
The 10-day RSI Indicator for COO moved out of overbought territory on February 03, 2023, which is a signal that the stock is potentially entering a bearish phase. This means that traders may want to consider selling the stock or buying put options to protect themselves from potential losses.
Tickeron's A.I.dvisor analyzed 37 instances where the RSI Indicator moved out of the overbought zone, and found that in 22 of those cases, the stock price moved lower in the days that followed. This puts the odds of a move down at 59%, which is a significant risk for investors.
Investors should generally consider the earnings announcement from Cooper Companies cautiously. Even if the company has a proven track record of success, current market signs point to a potential danger of a decline in the near term.
COO saw its Momentum Indicator move above the 0 level on June 27, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned positive. In of the 87 cases, the stock moved higher in the following days. The odds of a move higher are at .
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where COO's RSI Oscillator exited the oversold zone, of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for COO just turned positive on June 20, 2025. Looking at past instances where COO's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where COO advanced for three days, in of 294 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where COO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
COO broke above its upper Bollinger Band on July 01, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for COO entered a downward trend on June 12, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. COO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.563) is normal, around the industry mean (24.348). P/E Ratio (68.089) is within average values for comparable stocks, (77.706). Projected Growth (PEG Ratio) (12.258) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (5.400) is also within normal values, averaging (42.660).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. COO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a maker of medical devices
Industry MedicalSpecialties